Clinical Development Drugs Life Science Pharma Companies 
Pharmaceutical Technology
OCTOBER 28, 2022
Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development. Remote-controlled robotic labs.
Delveinsight
JULY 21, 2021
However, some of the key pharma companies at the global level have shifted their focus towards these diverse diseases. Through this article, we have covered the major autoimmune diseases and the key companies striving to transform the treatment landscape of the respective disease.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 3, 2020
The area is being reimagined as a life sciences and technology hub and is already home to the Francis Crick Institute biomedical research organisation. With AI the pharma industry hopes to reduce the number of drugs that fail during the clinical development process, a huge financial drain on the industry.
XTalks
OCTOBER 4, 2023
How is the shift toward value-based healthcare affecting drug pricing and reimbursement? There is a world where the way we have done things up until now from a pricing, health economics and access perspective is well-suited to meet the needs of drug reimbursement stakeholders, and where we would probably keep doing it.
XTalks
MAY 30, 2024
Over the years, his career has evolved from routine case processing at large pharma companies to a more strategic role in smaller settings, where he feels his impact more directly. He notes that the patient voice is critical, and with more involvement, patient advocacy groups will play an important role in clinical development.
XTalks
MARCH 28, 2024
Italy-based drugmaker Italfarmaco has won US Food and Drug Administration (FDA) approval for its oral medication Duvyzat (givinostat) for the treatment of Duchenne muscular dystrophy (DMD) in patients six years of age and older. The drug generated domestic sales of $200.4 million last year, of which $131.3
XTalks
JUNE 25, 2024
In the past two years, the industry has faced considerable challenges due to a constrained financing environment, forcing many emerging and early-stage biotech companies to restructure their operations, merge with other companies or narrow their research and development (R&D) efforts by shelving certain assets.
Expert insights. Personalized for you.
311 
Let's personalize your content